Instrument Business Outlook (IBO) has issued its annual forecast for 2026, assessing current market conditions across scientific sectors and instrument types, and making predictions for the coming year.
We thank IBO for its insightful forecast, published on 15th January in Volume 34: Issue 19 and for granting us permission to report on these findings. This blog summarises expectations for 2026, supported by data from Strategic Directions International (SDi). IBO and SDi are part of Science and Medicine Group, a leading research and advisory firm serving the life science, analytical instrument, diagnostic, healthcare, radiology and dental industries.
The analytical instrumentation industry went into 2025 with uncertainty due to geo-political and economic factors, and although it was expected to level out throughout the year, this proved not to be the case. In IBO’s mid-year forecast, the demand for instrumentation was predicted to increase low single digits whereas final estimates for the year now lie even lower at just over 1%.
Many markets, including biopharma, biotech, academia and government labs, stalled in 2025. However, industrial and applied markets did perform as expected and, in some cases, exceeded predicted performance.
Geographically, US and Chinese markets were negatively impacted by the incoming Trump Administration but in contrast, some of the best performing regions in terms of instrument demand growth were Europe and India.
For 2026, uncertainty and cautiousness remain high, therefore, IBO predicts a modest overall forecast of low single digit growth. External factors such as falling inflation rates, easing of capital constraints by central banks and stabilising of the US tariffs will influence the rate of growth throughout the year.
Demand is expected to expand for all ten technology areas within the lab instrument and product markets, with the biggest growth in chromatography, slated at mid-single digits, driven by the pharma industry in research and development (R&D) and quality control (QC) applications. The slowest growth is expected in lab equipment, estimated to be just above flat, with IBO citing long equipment lifespan and reduced levels of lab construction as the main factors.
The above graph shows how the instrument and laboratory product market moved from an extraordinary, pandemic-driven growth spike to a slower, more selective recovery. Revenues climbed sharply from 2020 to 2021 due to COVID testing and vaccine development. Growth rates then fell rapidly from 2022 through 2024 due to decreased demand, biotech funding and academic budgets. By 2025-2026, revenues are forecast to keep increasing toward mid-$80 billion, with growth expected at mid-single digits.
IBO, an SDi publication, is a subscription-based newsletter issued twice a month that covers the latest developments in the life science and analytical instrument industry. Learn more about IBO here.
SDi provides vendors in the analytical instrument and life science tools industries with important market research, enabling them to make informed decisions.
The Scott Partnership supports analytical instrumentation and life sciences businesses across the globe with market entry across local and international regions. Please get in touch to discuss your challenges and how we can help drive your business forward.